Anzeige
Mehr »
Donnerstag, 14.08.2025 - Börsentäglich über 12.000 News
Setup für DOGE & LTC Mining läuft an - und diese Aktie steht in der ersten Reihe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB38 | ISIN: US8334451098 | Ticker-Symbol: 5Q5
Tradegate
14.08.25 | 16:48
168,22 Euro
-0,08 % -0,14
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
SNOWFLAKE INC Chart 1 Jahr
5-Tage-Chart
SNOWFLAKE INC 5-Tage-Chart
RealtimeGeldBriefZeit
167,78168,0816:51
167,76168,0816:51
PR Newswire
153 Leser
Artikel bewerten:
(1)

Zifo Technologies: Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery

Zifo accelerates antibody engineering and therapeutics development with launch of AI-Powered Protein Models on Snowflake

CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Aug. 14, 2025 /PRNewswire/ -- Zifo announced the launch of its Antibody Engineering application, a cloud-native GenAI platform built on the Snowflake Data Cloud and available on the Snowflake Marketplace, which empowers biopharma companies, research institutions, and contract research organizations to design and optimize therapeutic antibodies faster and potentially shortening the timeline for new drug discovery without needing to move data outside of Snowflake.

The development of new antibody-based therapies is traditionally a complex, time-consuming, and expensive process. Zifo's Antibody Engineering app directly confronts this challenge by integrating state-of-the-art AI into a seamless, end-to-end workflow that promises to improve the hit rate for high-affinity therapeutic antibodies.

"We are entering a new era of drug discovery, one where AI and data converge to solve biology's most complex puzzles," said Chris McClure, Head of Solution Services for Zifo in North America. "Zifo Antibody Engineering is more than just a tool; it's a strategic partner for scientists. By building it as a Snowflake Native App, we're giving researchers the power to innovate faster, reduce R&D costs, and ultimately bring life-saving therapies to patients sooner. We've effectively democratized access to complex AI, removing the need for deep machine learning expertise."

Leveraging the power and scalability of Snowflake's platform, including Snowpark Container Services, the application provides a no-code, intuitive interface for scientists and bioinformaticians. Users can fine-tune powerful protein language models like ProtGPT2, RoBERTa, and ESM2 on their proprietary datasets without moving sensitive information outside of their secure Snowflake environment. The platform facilitates the entire discovery pipeline, from generating novel antibody sequences to predicting their 3D structures and analyzing key regions.

"Zifo Antibody Engineering, combined with Snowflake's infrastructure, offers life sciences a cutting-edge tool for research development," said Lisa Arbogast, Industry Principal for Healthcare and Life Sciences Ecosystem at Snowflake. "Together, we enable use of data to its fullest potential while helping customers adhere to high standards of security and compliance."

The value of Zifo's Antibody Engineering platform extends across the life sciences ecosystem:

  • Biopharma R&D Teams: Streamline antibody discovery by generating novel sequences and predicting binding affinities faster than traditional methods.
  • CDMOs and CROs: Offer AI-powered protein engineering as a service to clients developing therapeutic antibodies.
  • Academic and Research Institutions: Leverage advanced protein modeling tools to push the boundaries of computational biology and structural bioinformatics.
  • Clinical and Preclinical Development: Validate AI-generated antibodies with experimental data, expediting lead selection.

The architecture is designed for high-performance AI workloads, handling massive datasets and multi-modal inputs with ease, all within Snowflake's managed environment. After fine-tuning models, users can generate new antibody sequences, visualize their 3D protein structures, download PDB files, and review analysis of complementarity-determining regions (CDRs).

Zifo's Antibody Engineering App can be downloaded from Snowflake Marketplace here.

To access the Antibody Engineering App Documentation, please click here.

About Zifo

Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit zifornd.com.

Video: https://www.youtube.com/watch?v=CslVULoKlBU
Logo: https://mma.prnewswire.com/media/2731415/5460327/Zifo_Technologies_Logo.jpg

Zifo Technologies Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/zifo-launches-ai-antibody-engineering-app-on-snowflake-marketplace-to-accelerate-biologics-and-drug-discovery-302530081.html

© 2025 PR Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.